SCHEMBL765017

SCHEMBL765017

Cc1ccc(OCCCn2ccnn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.56
ATP4A P20648 1/20 0.52
ATP4B P51164 1/20 0.52
CYP19A1 P11511 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
HPGD P15428 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL763549 0.95 QPCT (0.51) QPCTATP4AATP4BCYP19A1SMN1; SMN2
SCHEMBL13246360 0.92 QPCT (0.50) QPCTATP4AATP4BCYP19A1SMN1; SMN2
SCHEMBL22397927 0.88 MEN1 (0.55) QPCTATP4AATP4BCYP19A1SMN1; SMN2
SCHEMBL13201562 0.87 ATP4A (0.53) ATP4AATP4BCYP19A1
SCHEMBL14189706 0.85 ATP4A (0.52) ATP4AATP4BCYP19A1MEN1KMT2A
SCHEMBL14996228 0.85 ATP4A (0.53) QPCTATP4AATP4BCYP19A1SMN1; SMN2
SCHEMBL5564341 0.84 ATP4A (0.52) QPCTATP4AATP4BCYP19A1RAB9A
SCHEMBL18837867 0.84 ATP4A (0.52) QPCTATP4AATP4BCYP19A1MEN1
SCHEMBL5046643 0.84 ATP4A (0.52) QPCTATP4AATP4BCYP19A1SMN1; SMN2
SCHEMBL16417747 0.84 MEN1 (0.59) ATP4AATP4BCYP19A1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732543-B1 TETRACYCLIC CARBOLINE DERATIVES FOR INHIBITING ANGIOGENESIS PTC THERAPEUTICS INC (US) 2017-05-10 EP disclosed
US-8940896-B2 Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2015-01-27 US disclosed
US-8940896-B2 Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2015-01-27 US disclosed
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 US disclosed
EP-2431369-A2 Carboline derivatives useful in the inhibition of angiogenesis PTC Therapeutics, Inc. (US) 2012-03-21 EP disclosed
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS PTC THERAPEUTICS, INC. 2010-07-15 US disclosed
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2010-06-24 US disclosed
US-7601840-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2009-10-13 US disclosed
US-20080182866-A1 Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis PTC THERAPEUTICS , INC. A CORPORATION 2008-07-31 US disclosed
US-20080182866-A1 Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis PTC THERAPEUTICS , INC. A CORPORATION 2008-07-31 US disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES RNMT, VEGFA, VHL QPCT 267/4885ATP4A 3565/4885ATP4B 4108/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF QPCT 1290/4885ATP4A 4522/4885ATP4B 4406/4885
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS VEGFA, FLT4, PGF QPCT 106/4885ATP4A 4494/4885ATP4B 4479/4885
US-20080182866-A1 Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis VEGFA, TEK, FLT4 QPCT 685/4885ATP4A 4387/4885ATP4B 4527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.